http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 08:02:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/ProKidney+names+Kenneth+Locke+as+chief+technical+officer/26587845.html <p>ProKidney Corp. (NASDAQ: PROK) announced the appointment of Kenneth Locke as Chief Technical Officer. The Winston-Salem, North Carolina-based cell therapy company focuses on chronic kidney disease treatments.</p><p>Locke joins ProKidney from Carisma Therapeutics, where he oversaw chemistry, manufacturing and controls, quality and regulatory functions for CAR Myeloid programs. He previously held leadership positions at Celgene, now part of Bristol Myers Squibb, where he led external manufacturing and strategic sourcing for cell therapy programs. At Novartis, he helped advance cell therapy programs and established global manufacturing capabilities.</p><p>"Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute http://www.streetinsider.com/Corporate+News/ProKidney+names+Kenneth+Locke+as+chief+technical+officer/26587845.html Tue, 02 Jun 2026 08:02:35 -0400 PROK http://www.streetinsider.com/Management+Changes/ProKidney+names+Kenneth+Locke+as+chief+technical+officer/26587845.html <p>ProKidney Corp. (NASDAQ: PROK) announced the appointment of Kenneth Locke as Chief Technical Officer. The Winston-Salem, North Carolina-based cell therapy company focuses on chronic kidney disease treatments.</p><p>Locke joins ProKidney from Carisma Therapeutics, where he oversaw chemistry, manufacturing and controls, quality and regulatory functions for CAR Myeloid programs. He previously held leadership positions at Celgene, now part of Bristol Myers Squibb, where he led external manufacturing and strategic sourcing for cell therapy programs. At Novartis, he helped advance cell therapy programs and established global manufacturing capabilities.</p><p>"Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute http://www.streetinsider.com/Management+Changes/ProKidney+names+Kenneth+Locke+as+chief+technical+officer/26587845.html Tue, 02 Jun 2026 08:02:35 -0400 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Press+Releases/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html <p>WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.<br/><br/>“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”</p> http://www.streetinsider.com/Globe+Newswire/ProKidney+Appoints+Kenneth+Locke+as+Chief+Technical+Officer/26587739.html Tue, 02 Jun 2026 08:00:00 -0400 A.13214750 A.39848620 O.01417635 O.02852348 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+DOYLE+WILLIAM+F/26575077.html si-local-file:///var/storage/secattach/20260529/26575077.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+DOYLE+WILLIAM+F/26575077.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+DOYLE+WILLIAM+F/26575077.html si-local-file:///var/storage/secattach/20260529/26575077.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+DOYLE+WILLIAM+F/26575077.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Fox+Jennifer+A./26575094.html si-local-file:///var/storage/secattach/20260529/26575094.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Fox+Jennifer+A./26575094.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Fox+Jennifer+A./26575094.html si-local-file:///var/storage/secattach/20260529/26575094.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Fox+Jennifer+A./26575094.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Jimenez+Santos+Jose+Ignacio/26575113.html si-local-file:///var/storage/secattach/20260529/26575113.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Jimenez+Santos+Jose+Ignacio/26575113.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Jimenez+Santos+Jose+Ignacio/26575113.html si-local-file:///var/storage/secattach/20260529/26575113.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Jimenez+Santos+Jose+Ignacio/26575113.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Lotvin+Alan/26575124.html si-local-file:///var/storage/secattach/20260529/26575124.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Lotvin+Alan/26575124.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Lotvin+Alan/26575124.html si-local-file:///var/storage/secattach/20260529/26575124.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Lotvin+Alan/26575124.html Fri, 29 May 2026 16:07:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Sinha+Uma/26574999.html si-local-file:///var/storage/secattach/20260529/26574999.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Sinha+Uma/26574999.html Fri, 29 May 2026 16:05:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Sinha+Uma/26574999.html si-local-file:///var/storage/secattach/20260529/26574999.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Sinha+Uma/26574999.html Fri, 29 May 2026 16:05:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Pereira+Brian+JG/26574945.html si-local-file:///var/storage/secattach/20260529/26574945.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+May+28++Filed+by%3A+Pereira+Brian+JG/26574945.html Fri, 29 May 2026 16:04:00 -0400 O.49464338 PROK